Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway

This research was designed to assess the inhibitory action of aliskiren, L-carnitine, and their combined treatment on JAK2/STAT3/SOCS3 signaling pathway in cardiac hypertrophy induced by isoproterenol injection rats. Wistar rats were injected with (5 mg/kg/day) for 15 days induction hypertrophy. Hypertrophied animals concurrently treated daily aliskiren (50 mg/kg) and/or L-carnitine (200 mg/kg). Either or significantly reduced elevated relative heart weight a concomitant reduction brain natriuretic peptide, creatine kinase-MB, troponin T animals. Additionally, myocardial interleukin-6, lipid peroxidation, markedly increased glutathione content. Aliskiren also attenuated fibrosis as evidenced significant decrease collagen I transforming growth factor-β1. The biochemical results further confirmed improvement histopathological architecture. Interestingly, down-regulated expression JAK2, STAT3, SOCS3 hypertrophied Conclusively, aliskiren/L-carnitine regimen may ameliorate through mitigating oxidative stress, inflammation, IL-6/JAK2/STAT3/SOCS3 pathway.